MicroRNAs in Cancer Treatment-Induced Cardiotoxicity
Open Access
- 17 March 2020
- Vol. 12 (3), 704
- https://doi.org/10.3390/cancers12030704
Abstract
Cancer treatment has made significant progress in the cure of different types of tumors. Nevertheless, its clinical use is limited by unwanted cardiotoxicity. Aside from the conventional chemotherapy approaches, even the most newly developed, i.e., molecularly targeted therapy and immunotherapy, exhibit a similar frequency and severity of toxicities that range from subclinical ventricular dysfunction to severe cardiomyopathy and, ultimately, congestive heart failure. Specific mechanisms leading to cardiotoxicity still remain to be elucidated. For instance, oxidative stress and DNA damage are considered key players in mediating cardiotoxicity in different treatments. microRNAs (miRNAs) act as key regulators in cell proliferation, cell death, apoptosis, and cell differentiation. Their dysregulation has been associated with adverse cardiac remodeling and toxicity. This review provides an overview of the cardiotoxicity induced by different oncologic treatments and potential miRNAs involved in this effect that could be used as possible therapeutic targets.Funding Information
- Ministero della Salute (RF-02362708, SG-12358253)
- National Institutes of Health (Intramural Research)
This publication has 170 references indexed in Scilit:
- Identification of the molecular basis of doxorubicin-induced cardiotoxicityNature Medicine, 2012
- Cell-specific effects of miR-221/222 in vessels: Molecular mechanism and therapeutic applicationJournal of Molecular and Cellular Cardiology, 2012
- miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibitionCell Death & Differentiation, 2011
- The ZEB/miR‐200 feedback loop—a motor of cellular plasticity in development and cancer?EMBO Reports, 2010
- A translational study of circulating cell-free microRNA-1 in acute myocardial infarctionClinical Science, 2010
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosisProceedings of the National Academy of Sciences of the United States of America, 2008
- Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposideBritish Journal of Pharmacology, 2006
- Targeted cancer therapyNature, 2004
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2003